{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T21:38:19.408304+00:00","company":{"ticker":"XNCR","cik":1326732,"company_name":"Xencor Inc"},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"812082bd67e0590aceb1957622735fdc0301e60b","cik":1326732,"ticker":"XNCR","company_name":"Xencor Inc","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$4.5 million"},"claim":"Xencor Inc reported the first quarter ended March 31, 2026 results: revenue $4.5 million. Guidance reaffirmed.","evidence_excerpt":"debt securities totaled $541.8 million as of March 31, 2026, compared to $610.8 million as of December 31, 2025. Revenue for the first quarter ended March 31, 2026 was $4.5 million, compared to $32.7 million for the same period in 2025. Revenue earned in the first quarter of 2026 was primarily non-cash royalty revenue from Incyte and Alexion, compared to","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001326732-26-000042","anchor_url":"https://secwatch.observer/filing/0001326732-26-000042#claim-812082bd67e0590aceb1957622735fdc0301e60b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673226000042/0001326732-26-000042-index.htm"},{"fact_type":"material_agreement","fact_key":"e69c2ed7ae4a7bc4926949540c211a59cafa53f8","cik":1326732,"ticker":"XNCR","company_name":"Xencor Inc","filed_at":"2026-03-09T23:59:59+00:00","payload":{"action":"termination","agreement_name":"Amended and Restated Collaboration and License Agreement","agreement_type":"collaboration","counterparty":"Genentech, Inc. and F. Hoffmann-La Roche Ltd","effective_date":"2026-09-04","item_codes_triggered":["1.02"],"value_text":null},"claim":"Xencor Inc terminated Amended and Restated Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd (effective 2026-09-04).","evidence_excerpt":"On March 4, 2026, Xencor, Inc. (the “Company”) received a notice of termination of an Amended and Restated Collaboration and License Agreement (the “Agreement”), effective as of June 1, 2024, with Genentech, Inc. (“GNE”) and F. Hoffmann-La Roche Ltd (“Roche” and, GNE and Roche, collectively, “Genentech”), pursuant to which Genentech has elected to terminate the Agreement in its entirety for convenience. The effective date of the termination of the Agreement is September 4, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001326732-26-000023","anchor_url":"https://secwatch.observer/filing/0001326732-26-000023#claim-e69c2ed7ae4a7bc4926949540c211a59cafa53f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673226000023/0001326732-26-000023-index.htm"},{"fact_type":"executive_change","fact_key":"add70724c8","cik":1326732,"ticker":"XNCR","company_name":"Xencor Inc","filed_at":"2025-05-07T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-06","interim":false,"role":"Executive Vice President and Chief Development Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Nancy Valente resigned as Executive Vice President and Chief Development Officer at Xencor Inc.","evidence_excerpt":"On May 5, 2025, Nancy Valente, Executive Vice President and Chief Development Officer, notified the Company of her intention to resign from the Company effective June 6, 2025, and remain as a senior advisor.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001326732-25-000052","anchor_url":"https://secwatch.observer/filing/0001326732-25-000052#claim-add70724c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000052/0001326732-25-000052-index.htm"},{"fact_type":"executive_change","fact_key":"fb28b351fd","cik":1326732,"ticker":"XNCR","company_name":"Xencor Inc","filed_at":"2025-03-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-13","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Todd Simpson was appointed as Director at Xencor Inc.","evidence_excerpt":"Todd Simpson was appointed to serve as a new member of the Board of Directors (the “Board”) of Xencor, Inc. (the “Company”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001326732-25-000035","anchor_url":"https://secwatch.observer/filing/0001326732-25-000035#claim-fb28b351fd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000035/0001326732-25-000035-index.htm"},{"fact_type":"executive_change","fact_key":"221cf38a17","cik":1326732,"ticker":"XNCR","company_name":"Xencor Inc","filed_at":"2024-10-04T23:59:59+00:00","payload":{"action":"not to stand for reelection","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dagmar Rosa-Bjorkeson departed as Director at Xencor Inc.","evidence_excerpt":"On September 30, 2024 Dagmar Rosa-Bjorkeson provided notice to the board of directors (the “Board”) of Xencor, Inc. (the “Company”) of her intent not to stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001326732-24-000052","anchor_url":"https://secwatch.observer/filing/0001326732-24-000052#claim-221cf38a17","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000052/0001326732-24-000052-index.htm"},{"fact_type":"earnings_release","fact_key":"1f337ced0df8ff67a83939c993448b477cb9839d","cik":1326732,"ticker":"XNCR","company_name":"Xencor Inc","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"$(1.11) on a fully diluted per share basis","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$68.0 million, or $(1.11) on a fully diluted per share basis","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$12.8 million"},"claim":"Xencor Inc reported the first quarter ended March 31, 2024 results: revenue $12.8 million, net income $68.0 million, or $(1.11) on a fully diluted per share basis, EPS $(1.11) on a fully diluted per share basis.","evidence_excerpt":"marketable debt securities totaled $646.7 million as of March 31, 2024, compared to $697.4 million on December 31, 2023. Revenues for the first quarter ended March 31, 2024 were $12.8 million, compared to $19.0 million for the same period in 2023. Total revenues earned in the first quarter of 2024 included non-cash royalty revenue from Xencor’s Alexion and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001326732-24-000030","anchor_url":"https://secwatch.observer/filing/0001326732-24-000030#claim-1f337ced0df8ff67a83939c993448b477cb9839d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000030/0001326732-24-000030-index.htm"}]}